Dyslipidemia in People Living with HIV on Anti-Retroviral Treatment: Case of the Ambulatory Treatment Center (ATC) of the Sylvanus Olympio University Hospital of Lome
Introduction: Dyslipidemia is a significant cardiovascular risk factor in patients living with HIV (PLWHIV). Few data are available in Togo. Objective: The purpose of this study is to assess the prevalence of dyslipidemia and associated factors in PLWHIV on Highly Active Antiretroviral Therapy (HAART). Methods: This is a descriptive and analytical cross-sectional study of patients followed at the Sylvanus Olympio University Hospital’s infectious diseases department for six months. The study population consisted of any PLWHIV patient on HAART over 18 years of age who had been regularly monitored and had a serum lipid fraction assay. Results: Two hundred and eighty-four patients were included. 75.4% were women. The median age was 46 years (IQR: 39 - 52) and the median CD4 count was 461 cel/U1 (IQR: 330 - 607). Eighty-three percent of the patients had suppressed viral load. The median duration of follow-up under antiretroviral treatment antiretroviral treatment was 4.18 years (IQR: 2 - 7). The prevalence of dyslipidemia was 72.5%. HDL hypocholesterolemia (HDL-c < 40 mg/dl) was the most represented dyslipidemia in 49.6%. Body mass index, past treated tuberculosis, HAART regimen substitution, abdominal obesity, past smoking and being exposed to Nucleoside reverse transcriptase inhibitors (NRITs) were found to be factors associated to dyslipidemia. Conclusion: Our study revealed a high prevalence of dyslipidemia in patients on HAART as well as associated factors. To this end, it is necessary to insist on screening for dyslipidemia before and after initiation of HAART in order to prevent the occurrence of cardiovascular events in PLWHIV.
References
[1]
Global HIV & AIDS Statistics—2018 Fact Sheet. http://www.unaids.org/en/resources/fact-sheet
[2]
Feeney, E.R. and Mallon, P.W.G. (2011) HIV and HAART-Associated Dyslipidemia. The Open Cardiovascular Medicine Journal, 5, 49-63. https://doi.org/10.2174/1874192401105010049
[3]
Bamba, V. and Rader, D.J. (2007) Obesity and Atherogenic Dyslipidemia. Gastroenterology, 132, 2181-2190. https://doi.org/10.1053/j.gastro.2007.03.056
[4]
Triant, V.A., Lee, H., Hadigan, C. and Grinspoon, S.K. (2007) Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease. The Journal of Clinical Endocrinology & Metabolism, 92, 2506-2512. https://doi.org/10.1210/jc.2006-2190
[5]
Nsagha, D.S., Weledji, E.P., Assob, N.J.C., Njunda, L.A., Tanue, E.A., kibu, O.D., et al. (2015) Highly Active Antiretroviral Therapy and Dyslipidemia in People Living with HIV/AIDS in Fako Division, South West Region of Cameroon. BMC Cardiovascular Disorders, 15, 95. https://doi.org/10.1186/s12872-015-0090-5
[6]
Tadewos, A., Addis, Z., Ambachew, H. and Banerjee, S. (2012) Prevalence of Dyslipidemia among HIV-Infected Patients Using First-Line Highly Active Antiretroviral Therapy in Southern Ethiopia: A Cross-Sectional Comparative Group Study. AIDS Research and Therapy, 9, 31. https://doi.org/10.1186/1742-6405-9-31
[7]
Pefura Yone, E.W., Betyoumin, A.F., Kengne, A.P., Kaze Folefack, F.J. and Ngogang, J. (2011) First-Line Antiretroviral Therapy and Dyslipidemia in People Living with HIV-1 in Cameroon: A Cross-Sectional Study. AIDS Research and Therapy, 8, 33. https://doi.org/10.1186/1742-6405-8-33
Bekolo, C.E., Nguena, M.B., Ewane, L., Bekoule, P.S. and Kollo, B. (2014) The Lipid Profile of HIV-Infected Patients Receiving Antiretroviral Therapy in a rural Cameroonian Population. BMC Public Health, 14, 236. https://doi.org/10.1186/1471-2458-14-236
[10]
Armstrong, C., Liu, E., Grinspoon, S., Okuma, J., Spiegelman, D., Guerino, C., et al. (2011) Dyslipidemia in an HIV-Positive, Antiretroviral Treatment-Naïve Population in Dar es Salaam, Tanzania. Journal of Acquired Immune Deficiency Syndromes, 57, 141-145. https://doi.org/10.1097/QAI.0b013e318219a3d1
[11]
Djibril, M.A., Balaka, A., Djagodou, K., Tchamdja, T., Bagny, A., Bougoulga, O., et al. (2012) Les dyslipidemies et antiretroviraux chez les personnes vivant avec le VIH dans le service de medecine interne au Chu-Tokoin de Lome. Journal de la Recherche Scientifique de l’Université de Lomé, 14, 45-49.
[12]
Buchacz, K., Weidle, P.J., Moore, D., Were, W., Mermin, J., Downing, R., et al. (2008) Changes in Lipid Profile over 24 Months among Adults on First-Line Highly Active Antiretroviral Therapy in the Home-Based AIDS Care Program in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes, 47, 304-311. https://doi.org/10.1097/QAI.0b013e31815e7453
[13]
Adébayo, A., Albert, D.C., Ericie, S., Angelo, A.C., Jules, G., Armand, W., et al. (2015) Prévalence, facteurs associés et prédisposant au syndrome métabolique chez les personnes vivants avec le VIH sous traitement antirétroviral à Porto-Novo en 2014. The Pan African Medical Journal, 22, 296. https://doi.org/10.11604/pamj.2015.22.296.7923
[14]
Daniel Seifu, E.B. (2014) Lipid Profile Derangements among Human Immunodeficiency Virus Infected Adults Receiving First Line Anti-Retroviral Therapy in Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: Comparative Cross-Sectional Study. Journal of AIDS & Clinical Research, 5, 328. https://doi.org/10.4172/2155-6113.1000328
[15]
Bernal, E., Masiá, M., Padilla, S. and Gutiérrez, F. (2008) High-Density Lipoprotein Cholesterol in HIV-Infected Patients: Evidence for an Association with HIV-1 Viral Load, Antiretroviral Therapy Status, and Regimen Composition. AIDS Patient Care STDs, 22, 569-575. https://doi.org/10.1089/apc.2007.0186
[16]
Abebe, M., Kinde, S., Belay, G., Gebreegziabxier, A., Challa, F., Gebeyehu, T., et al. (2014) Antiretroviral Treatment Associated Hyperglycemia and Dyslipidemia among HIV Infected Patients at Burayu Health Center, Addis Ababa, Ethiopia: A Cross-Sectional Comparative Study. BMC Research Notes, 7, 380. https://doi.org/10.1186/1756-0500-7-380
[17]
Kumar, P.N., Rodriguez-French, A., et al. (2006) A Prospective, 96-Week Study of the Impact of Trizivir, Combivir/Nelfinavir, and Lamivudine/Stavudine/Nelfinavir on Lipids, Metabolic Parameters and Efficacy in Antiretroviral-Naive Patients: Effect of Sex and Ethnicity. HIV Medicine, 7, 85-98. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1468-1293.2006.00346.x
[18]
Tarr, P.E., Rotger, M. and Telenti, A. (2010) Dyslipidemia in HIV-Infected Individuals: From Pharmacogenetics to Pharmacogenomics. Pharmacogenomics, 11, 587-594. https://doi.org/10.2217/pgs.10.35
[19]
Grunfeld, C. (2010) Dyslipidemia and Its Treatment in HIV Infection. Vol. 18, Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 112-118.
[20]
Domingos, H., da Cunha, R.V., Paniago, A.M.M., Martins, D.M., Elkhoury, E.B. and de Souza, A.S. (2009) Metabolic Effects Associated to the Highly Active Antiretroviral Therapy (HAART) in AIDS Patients. Brazilian Journal of Infectious Diseases, 13, 130-136. https://doi.org/10.1590/S1413-86702009000200012
[21]
Heath, K.V., Chan, K.J., Singer, J., O’Shaughnessy, M.V., Montaner, J.S.G. and Hogg, R.S. (2002) Incidence of Morphological and Lipid Abnormalities: Gender and Treatment Differentials after Initiation of First Antiretroviral Therapy. International Journal of Epidemiology, 31, 1016-1020. https://doi.org/10.1093/ije/31.5.1016
[22]
Young, J., Weber, R., Rickenbach, M., Furrer, H., Bernasconi, E., Hirschel, B., et al. (2005) Lipid Profiles for Antiretroviral-Naive Patients Starting PI- and NNRTI-Based Therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 10, 585-591.
[23]
Boothby, M., McGee, K.C., Tomlinson, J.W., Gathercole, L.L., McTernan, P.G., Shojaee-Moradie, F., et al. (2009) Adipocyte Differentiation, Mitochondrial Gene Expression and Fat Distribution: Differences between Zidovudine and Tenofovir after 6 Months. Antiviral Therapy, 14, 1089-1100. https://doi.org/10.3851/IMP1457
[24]
Brown, T.T., Li, X., Cole, S.R., Kingsley, L.A., Palella, F.J., Riddler, S.A., et al. (2005) Cumulative Exposure to Nucleoside Analogue Reverse Transcriptase Inhibitors Is Associated with Insulin Resistance Markers in the Multicenter AIDS Cohort Study. AIDS, 19, 1375-1383. https://doi.org/10.1097/01.aids.0000181011.62385.91
[25]
Dubé, M.P., Sprecher, D., Henry, W.K., Aberg, J.A., Torriani, F.J., Hodis, H.N., et al. (2000) Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clinical Infectious Diseases, 31, 1216-1224. https://doi.org/10.1086/317429
[26]
Padmapriyadarsini, C., Ramesh, K., Sekar, L., Ramachandran, G., Reddy, D., Narendran, G., et al. (2017) Factors Affecting High-Density Lipoprotein Cholesterol in HIV-Infected Patients on Nevirapine-Based Antiretroviral Therapy. Indian Journal of Medical Research, 145, 641.
[27]
Gebremicael, G., Amare, Y., Challa, F., Gebreegziabxier, A., Medhin, G., Wolde, M., et al. (2017) Lipid Profile in Tuberculosis Patients with and without Human Immunodeficiency Virus Infection. International Journal of Chronic Diseases, 2017, Article ID: 3843291. https://doi.org/10.1155/2017/3843291
[28]
Rose, H., Hoy, J., Woolley, I., Tchoua, U., Bukrinsky, M., Dart, A., et al. (2008) HIV Infection and High Density Lipoprotein Metabolism. Atherosclerosis, 199, 79-86. https://doi.org/10.1016/j.atherosclerosis.2007.10.018
[29]
Riddler, S.A., Li, X., Otvos, J., Post, W., Palella, F., Kingsley, L., et al. (2008) Antiretroviral Therapy Is Associated with an Atherogenic Lipoprotein Phenotype among HIV-1-Infected Men in the Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 48, 281-288. https://doi.org/10.1097/QAI.0b013e31817bbbf0
[30]
Riddler, S.A., Li, X., Chu, H., Kingsley, L.A., Dobs, A., Evans, R., et al. (2007) Longitudinal Changes in Serum Lipids among HIV-Infected Men on Highly Active Antiretroviral Therapy. HIV Medicine, 8, 280-287. https://doi.org/10.1111/j.1468-1293.2007.00470.x
[31]
Pischon, T., Boeing, H., Hoffmann, K., Bergmann, M., Schulze, M.B., Overvad, K., et al. (2008) General and Abdominal Adiposity and Risk of Death in Europe. The New England Journal of Medicine, 359, 2105-2120. https://doi.org/10.1056/NEJMoa0801891
[32]
Criqui, M.H., Wallace, R.B., Heiss, G., Mishkel, M., Schonfeld, G. and Jones, G.T. (1980) Cigarette Smoking and Plasma High-Density Lipoprotein Cholesterol. The Lipid Research Clinics Program Prevalence Study. Circulation, 62, IV70-IV76.
[33]
Batic-Mujanovic, O., Zildzic, M., Beganlic, A. and Kusljugic, Z. (2006) The Effect of Cigarette Smoking on HDL-Cholesterol Level. Medical Archives, 60, 90-92.
[34]
The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003) Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The New England Journal of Medicine, 349, 1993-2003. https://doi.org/10.1056/NEJMoa030218
